Avantor, Inc. with ticker code (AVTR) now have 18 analysts in total covering the stock. The consensus rating is pointing to ‘buy’. The range between the high target price and low target price is between 30 and 20 suggesting an average Analsyt target price of $25.06. Given that the stocks previous close was at $20.83 this would imply there is now a potential upside of 20.3%. The 50 day moving average now sits at $20.56 and the 200 day MA is $22.06. The company has a market cap of 14.10B. The stock price is currently at: 20.88 USD
The potential market cap would be $16,958,815,364 based on the market consensus.
The company is not paying dividends at this time.
Other points of data to note are a P/E ratio of 22.95, revenue per share of 11.01 and a 4.93% return on assets.
Avantor, Inc. is a global provider of mission-critical products and services to customers in the biopharma, healthcare, education and government, and applied materials industries. Its products include materials and consumables, equipment and instrumentation, and services and specialty procurement. Materials and consumables include chemicals and reagents, lab products and supplies, formulated silicone materials, customized excipients, customized single-use assemblies, process chromatography resins and columns, analytical sample prep kits and education and microbiology and clinical trial kits. Equipment and instrumentation include filtration systems, virus inactivation systems, incubators, analytical instruments, evaporators, freezers, biological safety cabinets and critical environment supplies. Services and specialty procurement include onsite lab and production, clinical, equipment, procurement and sourcing and biopharmaceutical material scale-up and development services.
